Current state of immune checkpoints therapy for glioblastoma

He Wang; Jing Yang; Xiangjun Li; Hai Zhao

doi:10.1016/j.heliyon.2024.e24729

Current state of immune checkpoints therapy for glioblastoma

Heliyon. 2024 Jan 13;10(2):e24729. doi: 10.1016/j.heliyon.2024.e24729. eCollection 2024 Jan 30.

Authors

He Wang¹, Jing Yang², Xiangjun Li³, Hai Zhao¹

Affiliations

¹ Department of Neurosurgery, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, China.
² Department of Emergency Surgery, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, Shandong, 266005, China.
³ School of medicine, Department of Breast surgery, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, 266000, China.

Abstract

Glioblastoma (GBM), one of the most aggressive forms of brain cancer, has limited treatment options. Recent years have witnessed the remarkable success of checkpoint inhibitor immunotherapy across various cancer types. Against this backdrop, several clinical trials investigating checkpoint inhibitors for GBM are underway in multiple countries. Furthermore, the integration of immunotherapy with traditional treatment approaches is now emerging as a highly promising strategy. This review summarizes the latest advancements in checkpoint inhibitor immunotherapy for GBM treatment. We provide a concise yet comprehensive overview of current GBM immunotherapy options. Additionally, this review underscores combination strategies and potential biomarkers for predicting response and resistance in GBM immunotherapies.

Keywords: Checkpoint inhibitor; Combination therapy; GBM; Immunotherapy.

Publication types

Review